144 related articles for article (PubMed ID: 34166770)
1. Targeting the Y-box Binding Protein-1 Axis to Overcome Radiochemotherapy Resistance in Solid Tumors.
Lettau K; Khozooei S; Kosnopfel C; Zips D; Schittek B; Toulany M
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):1072-1087. PubMed ID: 34166770
[TBL] [Abstract][Full Text] [Related]
2. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).
Reipas KM; Law JH; Couto N; Islam S; Li Y; Li H; Cherkasov A; Jung K; Cheema AS; Jones SJ; Hassell JA; Dunn SE
Oncotarget; 2013 Feb; 4(2):329-45. PubMed ID: 23593654
[TBL] [Abstract][Full Text] [Related]
3. Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation.
Toulany M; Schickfluss TA; Eicheler W; Kehlbach R; Schittek B; Rodemann HP
Breast Cancer Res; 2011 Mar; 13(2):R28. PubMed ID: 21392397
[TBL] [Abstract][Full Text] [Related]
4. Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer.
Panupinthu N; Yu S; Zhang D; Zhang F; Gagea M; Lu Y; Grandis JR; Dunn SE; Lee HY; Mills GB
Oncogene; 2014 May; 33(22):2846-56. PubMed ID: 23851501
[TBL] [Abstract][Full Text] [Related]
5. RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts.
Gieseler-Halbach S; Meltendorf S; Pierau M; Weinert S; Heidel FH; Fischer T; Handschuh J; Braun-Dullaeus RC; Schrappe M; Lindquist JA; Mertens PR; Thomas U; Brunner-Weinzierl MC
Cell Death Differ; 2017 Feb; 24(2):371-383. PubMed ID: 28009354
[TBL] [Abstract][Full Text] [Related]
6. Stress-Induced Phosphorylation of Nuclear YB-1 Depends on Nuclear Trafficking of p90 Ribosomal S6 Kinase.
Tiwari A; Rebholz S; Maier E; Dehghan Harati M; Zips D; Sers C; Rodemann HP; Toulany M
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30126195
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous Targeting of RSK and AKT Efficiently Inhibits YB-1-Mediated Repair of Ionizing Radiation-Induced DNA Double-Strand Breaks in Breast Cancer Cells.
Lettau K; Zips D; Toulany M
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):567-580. PubMed ID: 32931865
[TBL] [Abstract][Full Text] [Related]
8. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.
Stratford AL; Reipas K; Hu K; Fotovati A; Brough R; Frankum J; Takhar M; Watson P; Ashworth A; Lord CJ; Lasham A; Print CG; Dunn SE
Stem Cells; 2012 Jul; 30(7):1338-48. PubMed ID: 22674792
[TBL] [Abstract][Full Text] [Related]
9. Extracellular Signal-regulated Kinase (ERK)-dependent Phosphorylation of Y-Box-binding Protein 1 (YB-1) Enhances Gene Expression in Granulosa Cells in Response to Follicle-stimulating Hormone (FSH).
Donaubauer EM; Hunzicker-Dunn ME
J Biol Chem; 2016 Jun; 291(23):12145-60. PubMed ID: 27080258
[TBL] [Abstract][Full Text] [Related]
10. Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP).
Lou L; Wang J; Lv F; Wang G; Li Y; Xing L; Shen H; Zhang X
Cell Oncol (Dordr); 2021 Feb; 44(1):109-133. PubMed ID: 32894437
[TBL] [Abstract][Full Text] [Related]
11. YB-1 activating cascades as potential targets in KRAS-mutated tumors.
Khozooei S; Veerappan S; Toulany M
Strahlenther Onkol; 2023 Dec; 199(12):1110-1127. PubMed ID: 37268766
[TBL] [Abstract][Full Text] [Related]
12. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition.
Astanehe A; Finkbeiner MR; Krzywinski M; Fotovati A; Dhillon J; Berquin IM; Mills GB; Marra MA; Dunn SE
Oncogene; 2012 Oct; 31(41):4434-46. PubMed ID: 22249268
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.
Shiota M; Yokomizo A; Takeuchi A; Itsumi M; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Prostate; 2014 Jun; 74(9):959-69. PubMed ID: 24740858
[TBL] [Abstract][Full Text] [Related]
14. Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.
Shiota M; Itsumi M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Prostate; 2014 Jun; 74(8):829-38. PubMed ID: 24729449
[TBL] [Abstract][Full Text] [Related]
15. Y box binding protein 1 (YB-1) oncoprotein at the hub of DNA proliferation, damage and cancer progression.
Sangermano F; Delicato A; Calabrò V
Biochimie; 2020 Dec; 179():205-216. PubMed ID: 33058958
[TBL] [Abstract][Full Text] [Related]
16. YB-1 Oncoprotein Controls PI3K/Akt Pathway by Reducing Pten Protein Level.
Delicato A; Montuori E; Angrisano T; Pollice A; Calabrò V
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680946
[TBL] [Abstract][Full Text] [Related]
17. Y-Box Binding Protein 1 Stabilizes Hepatitis C Virus NS5A via Phosphorylation-Mediated Interaction with NS5A To Regulate Viral Propagation.
Wang WT; Tsai TY; Chao CH; Lai BY; Wu Lee YH
J Virol; 2015 Nov; 89(22):11584-602. PubMed ID: 26355086
[TBL] [Abstract][Full Text] [Related]
18. The human endonuclease III enzyme is a relevant target to potentiate cisplatin cytotoxicity in Y-box-binding protein-1 overexpressing tumor cells.
Guay D; Garand C; Reddy S; Schmutte C; Lebel M
Cancer Sci; 2008 Apr; 99(4):762-9. PubMed ID: 18307537
[TBL] [Abstract][Full Text] [Related]
19. MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop.
Sinnberg T; Sauer B; Holm P; Spangler B; Kuphal S; Bosserhoff A; Schittek B
Exp Dermatol; 2012 Apr; 21(4):265-70. PubMed ID: 22417301
[TBL] [Abstract][Full Text] [Related]
20. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
